Loading market movers...

REGN7945+Linvoseltamab

Phase 2

Regeneron Pharmaceuticals, Inc. (REGN)

Phase 2

Development Phase

0

Upcoming Catalysts

0

Historical Events

1

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

7 competitors in Relapsed/Refractory Multiple Myeloma

ACTICAR T-Cell Therapy

CBDYTeclistamab

View Full Landscape

Drug Information

Target Indication

Relapsed/Refractory Multiple Myeloma

Clinical Trial

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA4/23/2025

Lynozyfic

Monotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 3 prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.

Conditional

Drug Science

Mechanism of action & safety profile

Developer

REGN

Regeneron Pharmaceuticals, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)Phase 3

Macular Edema

VEGF Trap-Eye (BAY86-5321)Phase 3

Diabetes Mellitus

RamucirumabPhase 3

Recurrent Lung Non-Small Cell Carcinoma

Deferred afliberceptPhase 3

Diabetic Retinopathy

Etoposide PhosphatePhase 3

B-cell Non Hodgkin Lymphoma

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts